Shanghai, China

Weihong Nian

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 5.5

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2018-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: Weihong Nian: Innovator in Biopharmaceuticals

Introduction

Weihong Nian is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative therapeutic proteins. With a total of three patents to his name, Nian's work focuses on addressing critical health issues such as diabetes and cancer.

Latest Patents

One of Weihong Nian's latest patents is titled "Human CD47-targeting single-domain antibody and use thereof." This invention relates to an anti-CD47 single-domain antibody and its preparation method. The antibody comprises specific CDRs that are crucial for its functionality. Another notable patent is the "Long-acting blood sugar decreasing fusion protein." This invention provides a recombinant protein molecule that combines glucagon-like peptide-1 (GLP-1) with an immunoglobulin subtype Fc section. This fusion protein is designed to treat type II diabetes and obesity by effectively decreasing serum glucose levels and suppressing food intake.

Career Highlights

Weihong Nian has worked with several reputable companies in the biopharmaceutical sector. Notably, he has been associated with Genor Biopharma Co., Ltd. and Shanghai Escugen Biotechnology Co., Ltd. His experience in these organizations has allowed him to develop and refine his innovative ideas in the field.

Collaborations

Throughout his career, Weihong Nian has collaborated with various professionals in the industry. Some of his notable coworkers include Qing Zhou and Joe Zhou, who have contributed to his research and development efforts.

Conclusion

Weihong Nian's contributions to biopharmaceutical innovations highlight his role as a leading inventor in the field. His patents reflect a commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…